231 related articles for article (PubMed ID: 15199411)
21. Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors.
Khuda SE; Loo WM; Janz S; Van Ness B; Erickson LD
J Immunol; 2008 Dec; 181(11):7537-49. PubMed ID: 19017943
[TBL] [Abstract][Full Text] [Related]
22. Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc.
Swanson PJ; Kuslak SL; Fang W; Tze L; Gaffney P; Selby S; Hippen KL; Nunez G; Sidman CL; Behrens TW
J Immunol; 2004 Jun; 172(11):6684-91. PubMed ID: 15153484
[TBL] [Abstract][Full Text] [Related]
23. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
24. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
25. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation.
McNeil N; Kim JS; Ried T; Janz S
Genes Chromosomes Cancer; 2005 Jun; 43(2):137-46. PubMed ID: 15751044
[TBL] [Abstract][Full Text] [Related]
26. Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1.
Han SS; Shaffer AL; Peng L; Chung ST; Lim JH; Maeng S; Kim JS; McNeil N; Ried T; Staudt LM; Janz S
Mol Cancer; 2005 Nov; 4():40. PubMed ID: 16277667
[TBL] [Abstract][Full Text] [Related]
27. Bcl-2 expression is associated with poor prognosis of solitary plasmacytoma of bone.
Guo S; Zhi Y; Yang H; Yu Y; Wang Y; Zhang J; Wang G; Zhang L; Sun B; Zhang Y
Ann Hematol; 2014 Mar; 93(3):471-7. PubMed ID: 24013520
[TBL] [Abstract][Full Text] [Related]
28. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.
Greider C; Chattopadhyay A; Parkhurst C; Yang E
Oncogene; 2002 Nov; 21(51):7765-75. PubMed ID: 12420213
[TBL] [Abstract][Full Text] [Related]
29. Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.
Linden MA; Kirchhof N; Carlson CS; Van Ness BG
Exp Hematol; 2012 Mar; 40(3):216-27. PubMed ID: 22120021
[TBL] [Abstract][Full Text] [Related]
30. Hemopoietic neoplasms in lethally irradiated mice repopulated with bone marrow cells carrying the human c-myc oncogene: a repopulation assay.
Hirabayashi Y; Inoue T; Suda Y; Aizawa S; Ikawa Y; Kanisawa M
Exp Hematol; 1992 Feb; 20(2):167-72. PubMed ID: 1544384
[TBL] [Abstract][Full Text] [Related]
31. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
32. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations.
Silva S; Kovalchuk AL; Kim JS; Klein G; Janz S
Cancer Res; 2003 Dec; 63(24):8656-63. PubMed ID: 14695177
[TBL] [Abstract][Full Text] [Related]
33. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
34. A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.
Fiancette R; Amin R; Truffinet V; Vincent-Fabert C; Cogné N; Cogné M; Denizot Y
Leuk Res; 2010 Aug; 34(8):1043-51. PubMed ID: 20018375
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha.
Vail ME; Pierce RH; Fausto N
Cancer Res; 2001 Jan; 61(2):594-601. PubMed ID: 11212255
[TBL] [Abstract][Full Text] [Related]
36. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
37. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
38. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
[TBL] [Abstract][Full Text] [Related]
39. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
40. IL-6 transgenic mouse model for extraosseous plasmacytoma.
Kovalchuk AL; Kim JS; Park SS; Coleman AE; Ward JM; Morse HC; Kishimoto T; Potter M; Janz S
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1509-14. PubMed ID: 11805288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
